Kiniksa Pharmaceuticals International (KNSA) FCF Margin (2021 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly FCF Margin came in at 19.1% in Q2 2026, up 123.0% YoY from 8.57% in Q2 2025, and down 18.2% on a QoQ basis from 23.35% in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) FCF Margin (2021 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 6 years of FCF Margin data on file, last reported at 19.1% in Q2 2026.
- Quarterly FCF Margin rose 123.0% year-over-year to 19.1% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 21.48% (up 894.0% YoY) and the FY2025 annual result came in at 20.13%, up 1636.0% from the prior year.
- FCF Margin declined to 19.1% in Q2 2026, from 23.35% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 62.6% in Q3 2022 to a low of 105.91% in Q1 2022.
- A 5-year average of 5.32% and a median of 10.62% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin soared 47563 bps — and 2023, when it tumbled 3726 bps.
- Tracing KNSA's FCF Margin over 5 years: stood at 7.98% in 2022, then slipped by 14 bps to 6.87% in 2023, then jumped by 93 bps to 13.26% in 2024, then soared by 88 bps to 24.98% in 2025, then declined by 24 bps to 19.1% in 2026.
- The last three FCF Margin figures came in at 19.1% (Q2 2026), 23.35% (Q1 2026), and 24.98% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.07 Bn | 39.42 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.53 Bn | 29.85 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.13 Bn | 19.47 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.07 Bn | 5.54 Bn | 220.03 Mn | 19.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.10% |
| Mar 31, 2026 | 23.35% |
| Dec 31, 2025 | 24.98% |
| Sep 30, 2025 | 18.54% |
| Jun 30, 2025 | 17.87% |
| Mar 31, 2025 | 17.69% |
| Dec 31, 2024 | 13.26% |
| Sep 30, 2024 | -2.00% |
| Jun 30, 2024 | 1.22% |
| Mar 31, 2024 | 0.78% |
| Dec 31, 2023 | 6.87% |
| Sep 30, 2023 | 25.33% |
| Jun 30, 2023 | -5.36% |
| Mar 31, 2023 | -2.07% |
| Dec 31, 2022 | 7.98% |
| Sep 30, 2022 | 62.60% |
| Jun 30, 2022 | -28.40% |
| Mar 31, 2022 | -105.91% |
| Dec 31, 2021 | -112.61% |
| Sep 30, 2021 | -242.16% |